Balyasny Asset Management
OCUL icon

Balyasny Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Balyasny Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Buy
+975,200
New +$8.84M 0.01% 1073

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management's OCUL Position: Q2 2026 in Review

Balyasny Asset Management reduced its Ocular Therapeutix (OCUL) stake by 16% in Q2 2026, selling an estimated $3.82M and leaving 2,270,707 shares worth $22.3M. The position accounts for 0.03% of the portfolio, ranked #664.

Balyasny Asset Management first reported a position in OCUL in Q1 2016 and has held it in 16 quarters since. The position peaked at $25.6M in Q3 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Balyasny Asset Management held 2,270,707 shares of Ocular Therapeutix worth $22.3M as of Q2 2026.
  • Balyasny Asset Management sold 421,915 Ocular Therapeutix shares in Q2 2026, an estimated $3.82M.
  • Ocular Therapeutix made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #664 holding.
  • Balyasny Asset Management first reported a position in Ocular Therapeutix in Q1 2016 and has held it in 16 quarters since.
  • Balyasny Asset Management's Ocular Therapeutix position peaked at $25.6M in Q3 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.